‘Covid fog’: The latest emerging, long-term symptom of Covid-19 – The Daily Briefing

Up to one-third of people who had Covid-19 report lingering neurological and psychological symptoms due to the disease, ranging from numb limbs to a mental slowness some people are calling "Covid fog"a finding that "reflect[s] a growing consensus that the disease can have lasting impact on the brain," Elizabeth Cooney reports for STAT News.

How Covid-19 will impact behavioral health services

According to Cooney, early reports from China and Europe revealed that some patients recovering from Covid-19, the disease caused by the new coronavirus, experienced anxiety and depression. Further, experts told STAT News that, in addition to mood disorders, they've seen patients who recovered from their coronavirus infections experience neuropsychological symptoms including dizziness, numbed limbs, brain fog, long-term loss of smell and taste, muscle weakness, and nerve damage so severe that patients struggled to walk. And that's on top of the long-term physical symptoms Covid-19 can cause, including damage to the heart, kidneys, and liver, Cooney reports.

Teodor Postolache, a professor of psychiatry at the University of Maryland School of Medicine, estimates that "between 30% and 50% of people with [a coronavirus] infection that has clinical manifestations are going to have some form of mental health issues," ranging from "anxiety or depression but also nonspecific symptoms that include fatigue, sleep, and waking abnormalities, a general sense of not being at your best, not being fully recovered in terms of the abilities of performing academically, occupationally, potentially physically."

John Bonfiglio, 64, reported many such symptoms after he recovered from a serious bout with Covid-19 at Newton-Wellesley Hospital, Cooney reports. Once Bonfiglio was finally transferred out of the ICUafter spending 17 days on a ventilatorhe said he was so confused that he forgot his name, forget where he was, and sometimes tried to slide from his bed to the floor.

Bonfiglio said he also felt more emotional than usual during his recovery and experienced persistent dizziness, hand tremors, and muscle weaknessso much so that he had to relearn how to walk. Bonfiglio said he's since regained some strength and the dizziness and tremors are now gone.

Similarly, Fred Pelzman, an internal medicine physician from New York who fell ill with Covid-19 in March, said he is still experiencing symptoms of the disease, including depressed abilities to taste and smell. And, according to Pelzman, his patients also have reported lingering effects from Covid-19, with one unable to complete simple math calculations in her head and others struggling to find correct words when communicating.

According to Cooney, researchers at the moment can say little "definitively about how best to prevent and treat neuropsychological manifestations of Covid-19. Nor do they know for certain why the brain is affected."

Victoria Pelak, a professor of neurology and ophthalmology at the University of Colorado School of Medicine, said treating Covid-19 patients with neurological symptoms has been like "trying to put out the fire." She explained, "Because you are so concerned with the raging fire," of Covid-19, "you haven't really been able to pay attention to the nervous system as much as you normally would."

But doctors have started putting some pieces together, Cooney writes. They think, for instance, that the new coronavirus damages the brain and nervous symptom through inflammation, not through a direct attack on those systems.

Lena Al-Harthi, chair of the department of microbial pathogens and immunity at Rush Medical College, explained that bits of the virusrather than the virus multiplyingcan spur the brain's inflammatory response.

"If you have an uncontrolled level of inflammation, that leads to toxicity and dysregulation," Al-Harthi said. "What I am concerned about is long-term effects, obviously in the [Covid-19 patients] who have been hospitalized, but I think it's definitely time to understand long-term sequelae for those individuals who have never been hospitalized"and it's not just limited to "older individuals," but includes "young [ones], too."

Physicians also are assessing whether the novel coronavirus is more likely than other viruses to cause a syndrome called demyelination, in which inflammation in the brain causes the immune system to attack the protective coating of nerve cells, Pelak said. According to Cooney, the syndrome can "cause weakness, numbness, and tingling. It can also disrupt how people think, in some cases spurring psychosis and hallucinations."

As for treating and preventing these longer-term issues, Ross ZafonteCMO at Spaulding Rehabilitation Hospital, which provides care to recovering Covid-19 patientssaid he's "trying to do a longitudinal study to see what are the comorbid factors." According to Zafonte, questions that need to be answered include: "What are the characteristics of people who don't get back to normal? How can early intervention try to deal with that? Are there some biomarkers of risk? [and] Can we try to define better targets for early intervention?"

Some physicians have voiced concerns about the long-term outlook for individuals who were infected with the coronavirus and are experiencing these symptoms. Postolache, for instance, said a coronavirus infection might serve as a "priming event," meaning that future stressors may reactivate the emotional and behavioral symptoms originally spurred by the infection. "We don't really say this is permanent," he said, "but considering all complexities of human life, it's unavoidable."

Wes Ely, a pulmonologist and critical care physician at Vanderbilt University Medical Center, echoed similar concerns, noting that while researchers will continue psychiatric evaluations and diagnostic imaging to get to the bottom of the symptoms, everything physicians know about the neurological symptoms of Covid-19 so far indicate that the disease could be "not only an acute problem," but "a chronic illness." Ely added, "The problem for these people is not over when they leave the hospital."

Keeping those factors in mind, Ely recommended three steps providers can take now to address the issue: "We can open the hospitals back up to the families" so patients are less isolated, "tell the families about [this issues] so that the families will know that this is coming," and offer "counseling and psychological help on the back end" (Cooney, STAT News, 8/12).

See the original post:
'Covid fog': The latest emerging, long-term symptom of Covid-19 - The Daily Briefing

Higgins announces $2.2 million grant to UB to support Parkinson’s research – UB Now: News and views for UB faculty and staff – University at Buffalo…

Rep. Brian Higgins has announced that UB has received a five-year, $2,224,925 grant from the National Institutes of Health to develop a method to diagnose Parkinsons disease (PD) before clinical symptoms are present.

The funding was awarded by the National Institute of Neurological Disorders and Stroke of the NIH. Principal investigator is Jian Feng, professor of physiology and biophysics in the Jacobs School of Medicine and Biomedical Sciences at UB.

Parkinsons is a motor system disorder resulting from the loss of dopamine-producing cells in the brain. It currently is diagnosed by neurologists observing and rating clinical symptoms based on a standard criteria. To even exhibit the onset of clinical symptoms of PD, one must experience many decades of cellular deterioration.

UBsresearch aims to transform Parkinsons research and therapeutic development with the ability to diagnose PD earlier, allowing for the possibility of proactively preventing or delaying severe neuron decay. The research, titled Molecular Segregation of Parkinsons Disease by Patient derived Neurons will also aim to identify and separate two major subtypes of PD those who experience tremors and those who do not to be able to better treat specific types of PD.

The National Institutes of Health estimates that up to 1 million people in the United States may have Parkinsons disease. Thats 1 million Americans with a difficult, progressive condition without a cure who must wait until their clinical symptoms are serious enough to be diagnosed, Higgins said. This federal investment to assist our Western New York researchers hopes to provide a path to earlier detection of Parkinsons to attempt treatment as quick as possible.

When we generated induced pluripotent stem cells from a group of Parkinsons disease patients and a group of normal subjects, we found that there were many significant differences in the expression levels of genes controlling the production, utilization and degradation of dopamine, Feng said. Thus, we want to investigate this further with the goal of developing a method for the objective diagnosis of Parkinsons disease. It might also allow us to predict years in advance who may develop Parkinsons.

Higgins has been an advocate for measures that advance Parkinsons research and treatment.Following meetings with the Michael J. Fox Foundation,the Parkinsons Foundation of WNY and local advocate and former congressman Jack Quinn, Higgins sent a letter to the Department of Veterans Affairs and the Department of Health and Human Services last January urging that access to boxing therapy in the treatment of Parkinsons be expanded, as well as more research be conducted to document the efficacy of the program.In February, he drafted a bipartisan letter supporting funding for a surveillance database at the Centers for Disease Control and Prevention to collect vital demographic information on people living with neurological diseases,a measure supported by the Michael J. Fox Foundation.

Go here to see the original:
Higgins announces $2.2 million grant to UB to support Parkinson's research - UB Now: News and views for UB faculty and staff - University at Buffalo...

Neurology Study: Contact Sports and Concussion in Rugby – LWOR – Last Word On Rugby

In a study that compared Rugby Players to Swimmers and Rowers, study author Ravi S. Menon, Ph.D., FRSC, of Western University in London, Canada, found that contact sports have a correlation with brain damage and concussion.

According to a new study published in the June 17, 2020, online issue of Neurology, the medical journal of theAmerican Academy of Neurology, the study compared rugby players to other female college athletes competing in the non-contact sports of swimming and rowing.

101 female college athletes took part in the study. This included 70 rugby players and 31 rowing or swimming athletes. The study followed a subset of the rugby players for at least two years. It also followed swimmers and rowers for one year.

In terms of rugby union, the fact that the tackler and the tackled player are at risk, is well established. What this study has found is that exposure at any level, can result in changes to a player [subject] microstructure of the white matter, including in nerve fibers that connect areas of the brain. This white matter controls basic emotions like fear, pleasure, and anger. In some of the rugby players, the changes progressed over time.

While any contact sport such as football, basketball, and American Football may result in injury. Rugby, with players intent to stop the forward progress of the opposition, putting bodies and especially heads, in a compromised position (in the contact area). These results indicate that only after a short term, affects can be found more in rugby union. More so than in non-contact sports.

Even with no concussions, the repetitive impacts experienced by the rugby players [even during training] clearly had effects on the brain, said Menon.

Researchers used magnetic resonance imaging (MRI) to scan the brains of all the athletes during in- and off-season play. With the brain scans, researchers examined how water molecules moved throughout the white matter. This was to determine if there were microstructural brain changes.

Researchers found differences in the functional organization of the brain too. When compared to swimmers and rowers, rugby players had changes in connectivity. How the brain communicates between the areas of the brain that control memory retrieval and visual processing.

While we only looked at these impacts during a few events during the season, previous research has shown these kinds of subclinical impacts may accumulate over years of participation in contact sports.

More research is needed to understand what these changes may mean and to what extent they reflect how the brain compensates for the injuries, repairs itself or degenerates so we can better understand the long-term health effects of playing a contact sport.

With growing evidence of new and established studies, many will conclude that the game is counter-productive. The risk is too large. Current players will, and continue to suffer from injury due to contact sports activity.

HIA tests today are risk-averse, to remove any player from harm. This head injury assessment can mean the difference between a serious injury and player welfare. Although, the results of the study by Western University prove that any exposure is harmful.

Head injury protocols have been issued by World Rugby. Players should aim to lower the tackle area. Promoting less impact that includes the head area should improve the welfare of players. Yet at the center of the argument is, that it is the choice of the individual.

In time, rule variations, reduced emphasis in the breakdown, changes to contact sports like rugby may alter the sport. But, the focus will and should focus on health and welfare first.

___________________________________

The study was supported by the Schulich School of Medicine & Dentistry at Western University, the Canadian Institutes for Health Research, Brain Canada, Canada First Research Excellence Fund, and the Natural Sciences and Engineering Research Council of Canada.

Main photo creditEmbed from Getty Images

More:
Neurology Study: Contact Sports and Concussion in Rugby - LWOR - Last Word On Rugby

icometrix named to the 2020 CB Insights Digital Health 150 – List of Most Innovative Digital Health Startups – PRNewswire

NEW YORK, Aug. 13, 2020 /PRNewswire/ --CB Insights today named icometrix to its second annual Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world.

The 2020 Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare experience across 12 categories, from Virtual Care Delivery and Clinical Trials, to Drug Discovery and Specialty Care.

"This year's Digital Health 150 is our most global ever, covering the best private healthcare companies from 17 countries. Beyond geographic diversity, these companies are innovating across the entire healthcare value chain, spanning technologies that benefit pharma & biotech companies, to payers, hospitals, insurers, and more," said CB Insights CEO Anand Sanwal.

"We are honored to receive this renewed recognition by CB Insights," said Wim Van Hecke, CEO of icometrix. "Innovative digital health solutions are changing healthcare at a rapid pace. Through our brain MRI and CT measures, we help radiologists, neurologists, neurosurgeons, and their referring physicians to make more informed and more accurate decisions for patients with neurological disorders. With our recently launched icompanion, a free app for people with multiple sclerosis to track symptoms, treatments, physician visits, as well as view their MRI scans on-the-go. All of this contributes to enhanced patient care worldwide, providing individual patients with the right treatment at the right moment," Van Hecke concludes.

icometrix offers AI solutions to obtain clinically meaningful data from MR and CT scans. Its icobrain portfolio incorporates brain volumetrics for patients with neurological conditions in clinical practice. icolung, an AI solution launched to help fight COVID-19, quantifies lung pathology on chest CT in admitted COVID-patients. Today, icometrix is internationally active in over 100 clinical practices and works with healthcare providers and pharmaceutical companies on the evaluation of drug trials for neurological diseases.

About icometrix icometrix (Leuven, Belgium; Chicago, USA) is the world leader in software solutions to obtain clinically meaningful data from brain MRI and CT scans. The fully automated icobrain software has market clearance in the USA, Europe, Japan, Canada, Brazil, India, and Australia. Today, the icobrain portfolio is used in patients with multiple sclerosis, dementia, and brain trauma.

Contact: Wim Van Hecke, CEO[emailprotected]+32 16-369-000icometrix.com

Press Kit:https://icometrix-files.s3-eu-west-1.amazonaws.com/Press-releases/Press-Kit-icometrix-20200813.zip

SOURCE icometrix

http://icometrix.com

Read the original:
icometrix named to the 2020 CB Insights Digital Health 150 - List of Most Innovative Digital Health Startups - PRNewswire

Interventional Neurology Device Market by Type, Application, Element Global Trends and Forecast to 2025 – 3rd Watch News

Market Study Report LLC has added a new report on Interventional Neurology Device Industry Market Size that provides a comprehensive review of this industry with respect to the driving forces influencing the industry. Comprising the current and future trends defining the dynamics of this industry vertical, this report also incorporates the regional landscape of Interventional Neurology Device Industry market in tandem with its competitive terrain.

The Interventional Neurology Device Industry market report is an in-depth analysis of this business space. The major trends that defines the Interventional Neurology Device Industry market over the analysis timeframe are stated in the report, along with additional pointers such as industry policies and regional industry layout. Also, the report elaborates on the impact of existing market trends on investors.

Request a sample Report of Interventional Neurology Device Industry Market at:https://www.marketstudyreport.com/request-a-sample/2728328

COVID-19, the disease it causes, surfaced in late 2020, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.

Other information included in the Interventional Neurology Device Industry market report is advantages and disadvantages of products offered by different industry players. The report enlists a summary of the competitive scenario as well as a granular assessment of downstream buyers and raw materials.

Revealing a gist of the competitive landscape of Interventional Neurology Device Industry market:

Ask for Discount on Interventional Neurology Device Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2728328

An outlook of the Interventional Neurology Device Industry market regional scope:

Additional takeaways from the Interventional Neurology Device Industry market report:

This report considers the below mentioned key questions:

Q.1. What are some of the most favorable, high-growth prospects for the global Interventional Neurology Device Industry market?

Q.2. Which products segments will grow at a faster rate throughout the forecast period and why?

Q.3. Which geography will grow at a faster rate and why?

Q.4. What are the major factors impacting market prospects? What are the driving factors, restraints, and challenges in this Interventional Neurology Device Industry market?

Q.5. What are the challenges and competitive threats to the market?

Q.6. What are the evolving trends in this Interventional Neurology Device Industry market and reasons behind their emergence?

Q.7. What are some of the changing customer demands in the Interventional Neurology Device Industry Industry market?

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-interventional-neurology-device-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. COVID-19 Outbreak-Global Testosterone Booster Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-testosterone-booster-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

2. COVID-19 Outbreak-Global Thin Film Drug Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-thin-film-drug-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the article here:
Interventional Neurology Device Market by Type, Application, Element Global Trends and Forecast to 2025 - 3rd Watch News

Accentuate the Positive: Appreciative Inquiry as a Tool for… : Neurology Today – LWW Journals

Article In Brief

One academic medical center has put into place a wellness program, based on the concept of appreciative inquiry, which asks neurology residents to explore their existing strengths and successes.

Christopher Traner, MD, a chief neurology resident at Yale School of Medicine, had become familiar with common approaches to combating physician and resident burnoutprograms aimed at building resiliency in individual clinicians, such as mindfulness coaching, and efforts to identify and combat the stress factors, like a massive firehose-worthy flow of medical data to manage, that lead to burnout.

But when his assistant program director, Jeffrey Dewey, MD, assistant professor of neurology, invited him to be a part of a group of eight residents to do hour-long face-to-face interviews on a strategy for burnout prevention called Appreciative Inquiry, Dr. Traner was intrigued. It sounded very different from anything I'd participated in before, he said.

Appreciative Inquiry (AI) is a strengths-based, positive approach to leadership development and organizational change. Instead of approaches like a SWOT (strengths, weaknesses, opportunities and threats) analysis, which spend significant time on pitfalls and problems, AI asks people to explore strengths and successes that already exist.

At its heart, AI is about the search for the best in people, their organizations, and the strengths-filled, opportunity-rich world around them, wrote David Cooperrider, PhD, a Distinguished University Professor at Case Western University and the originator of the concept, in a 2015 book on the appreciative inquiry process.

AI is not so much a shift in the methods and models of organizational change, but AI is a fundamental shift in the overall perspective taken throughout the entire change process to see the wholeness of the human system and to inquire into that system's strengths, possibilities, and successes.

Dr. Dewey can't remember where he first came across the concept of AI, but it immediately struck a chord with him. I've always been very interested in positive psychology and optimal human performance, so it really resonated with my world view, he said. He had also learned of a few academic medical centers that had applied AI across their institutions, including Indiana University School of Medicine and the University of Virginia Health System, which now has a Center on Appreciative Practice that has published a book on appreciative inquiry in health care.

So when he was selected to participate in the AAN's Live Well, Lead Well program, in which clinicians develop project-based initiatives for improving practice culture and reducing burnout, he decided it was the perfect opportunity to put AI into practice in the Yale neurology residency program.

The full AI process is a cycle of five Ds, including Definition, Discovery, Dream, Design, and Destiny/Delivery; Dr. Dewey focused his project on the discovery phase, which involves interviewing stakeholders in an organization about what is working well and gives life to the institution.

In the era of burnout, we know really well what isn't working, he said. It's easy to become focused on that and forget about the best of what we do. I wanted to understand what we were doing well and what helped the residents thrive, and to teach them this mode of thinkinghow to focus on what's going well around them.

In the pilot series of one-on-one interviews, Dr. Dewey spoke with Dr. Traner and seven other residents about how they found pleasure in their work and the things that motivated them to keep coming back. When in their residency did they feel at their absolute best? What circumstances led to those feelings?

One thing he asked me was, Tell me about a patient you recently cared for where you had a positive experience, Dr. Traner recalled. As I began talking about patients I had cared for and positive interactions with them and their families, I realized how easy it is for those things to get lost in the day to day minutiae of being at work, writing notes, and helping discharge patients. It's easy to lose focus on why you went into medicine in the first place.

For example, Dr. Traner, who will stay at Yale for an epilepsy fellowship after completing his residency, told Dr. Dewey about a patient who works maintaining and supplying swimming pools.

He was having trouble accessing care for his epilepsy because his work is so seasonal, and hospital admissions for epilepsy monitoring units are typically most open in the summer, Dr. Traner said. So I spent a lot of time working with him and eventually spoke to his boss and got a dispensation for him to take off work for an EMU admission. We were able to characterize his seizures and with medication adjustments, he's now been seizure-free for two years and it's really made all the difference in his life. This is one of the reasons I chose epilepsy as a subspecialty: people don't realize the toll a disease like that can take on someone, particularly with the social stigma. His positive experience is one that I always think about.

One surprising common theme that arose during these hour-long interviews, which were conducted under the auspices of an IRB-compliant study, was that of residents reporting some of their most positive experiences when pushed beyond their comfort zone.

To a person, they all reported feeling positive about going through a clinical experience that stressed themlike the first time they covered call overnightand being able to overcome that challenge, said Dr. Dewey.

For example, one resident described being early in their residency and doing a very intense emergency department shift where there were multiple stroke alerts and they felt like they were out of their element. But then later it hit them: I'm doing this. I'm a neurologist now. This goes with the positive psychology concept of eustress, stress that leads to growth. Most people were not necessarily enjoying themselves in the moment, but as they reflected on those experiences, they saw them as some of the best moments of their residency.

Almost all of these experiences involved situations in which the residents were required to act independently, with little or no supervision. This suggests that we should focus on setting our residents up for experiences in which they are highly challenged, and yet have the opportunity to grow, Dr. Dewey said. And then we need to give them the opportunity to reflect on those experiences in a structured way, because the reflection is just as important as the experience itself to the appreciative inquiry process. That could be done in the moment, immediately afterward, or at a later time. But it should not be just once a year or once in a residency. We are great at setting up regular opportunities for our residents to debrief critical incidents or bad outcomes with things like morbidity and mortality conferences, but not so great at doing the same with moments of success and growth.

After the eight one-on-one pilot interviews, Dr. Dewey assembled a larger focus group of all the neurology residents and paired them up to discuss what their ideal practice environment would look like, if there were no barriers.

We brainstormed all kinds of ideas, like protected time for case conferences where some other entity could take care of the patients so we could focus on our discussion and our learning, said Dr. Traner. No ideas were off limits. Then we talked about how to take baby steps toward some of those goals and making them achievable. Having a positive attitude about work and making people feel appreciated at work is so important. You don't want to distract people from what the problems are, but rather, address them in a positive way.

Jennifer Rose V. Molano, MD, FAAN, associate professor of neurology at the University of Cincinnati, FAAN, co-chair of the AAN's Wellness Joint Coordinating Council, and chair of the Live Well, Lead Well program said that Dr. Dewey's project was a natural fit, and could easily be replicated at other institutionsindeed, her department has already done so.

Our chair, Dr. Brett Kissela, really believes in the idea that we need to take care of ourselves so that we can take care of our patients, she said. At our last half-day retreat for about 200 members of our departmentfaculty, learners and administrative, clinical and research staffwe included two appreciative inquiry exercises focused on joy in work and high-functioning teams.

We had groups of ten per table, and each table had individual reflections followed by a table discussion, which they wrote up on a feedback sheet that was returned to leadership, Dr. Molano said.

What I like about AI is that it provides us with the opportunity to take a strength-based approach for growth within a group or department. Particularly in this time of tremendous change and uncertainty, it's important to use positive psychology techniques to figure out where our strengths are as we try to navigate this rapidly evolving new landscape.

Originally posted here:
Accentuate the Positive: Appreciative Inquiry as a Tool for... : Neurology Today - LWW Journals

Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine – P&T Community

SEATTLE, June 10, 2020 /PRNewswire/ --Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced positive results from "STOP 301" (Safety and Tolerability of POD-DHE), the Company's pivotal Phase 3, open-label study of the safety and tolerability of INP104 (dihydroergotamine mesylate) or DHE, administered to the vascular rich upper nasal space via Impel's proprietary POD technology, for the treatment of acute migraine. The study, which treated over 5,650 migraine attacks, evaluated self-administered, intermittent use of INP104 for up to 52-weeks, and also collected in a diary exploratory efficacy data of INP104 as assessed by patient reported change from baseline in migraine measures during the course of the study.

Results showed the STOP-301 study met its primary objectives, with no new safety signals or concerning trends in nasal safety findings observed for INP104 following delivery of DHE to the upper nasal space. DHE is a molecule long relied upon for its high response rate and sustained efficacy. Its use has been limited in part by its availability only as an invasive injectable or in other delivery forms with high dosing variability. In the study, the majority of treatment-related adverse events for the 24-week Full Safety Set (FSS) (n=354) were mild and transient in nature. The most frequently reported adverse events (5%) during the entire 24-week period were nasal congestion (15.0%), nausea (6.8%), nasal discomfort (5.1%) and unpleasant taste (5.1%). The majority of patients (74% and 90%) completed the 24- and 52-week phases of the study, respectively. No drug-related serious adverse events (SAEs) were observed over the entire 52-week study.

"Despite historically being known as a highly effective treatment, use of DHE in the treatment of acute migraine has been limited due to dose-related side effects, inadequate or inconvenient routes of administration and high variability in dose delivered, making these data highly encouraging for clinicians who need an at-home option that also has the benefit of broad neurogenic activity," said Stewart J. Tepper, M.D., Professor of Neurology at the Geisel School of Medicine at Dartmouth and Director of the Dartmouth Headache Center in the Department of Neurology of Dartmouth-Hitchcock Medical Center. "Interestingly, an increased recognition of the link between migraine and gastrointestinal issues may be why nearly 60 and 90 percent of patients with migraine experience vomiting and nausea, respectively, during an attack which presents limitations for the use of oral therapies. If approved, INP104 has the potential to offer patients a non-oral alternative with an all-in-one approach to treating the whole migraine due to DHE's broad receptor binding profile.i"

In the study, INP104 delivered 1.45 mg of DHE, less than 72.5% of the currently approved dose (2.0 mg). Optimal dosing is critical so that patients may stand to benefit from the established efficacy profile of DHE, without the potentially triggering undesired side effects that can be experienced with delivering higher doses of drug to the lower nasal space. Per the approved product label for Migranal, the U.S. Food & Drug Administration (FDA) currently limits the maximum dose of DHE to 6.0 mg a week.

Exploratory efficacy data in the FSS (n=354) observed that 66.3% of patients achieved pain relief and 38% of patients achieved pain freedom at two hours following their first dose of INP104. In the Primary Safety Set (PSS) (n=185), 33.1% of patients who took an average of two or more treatments with INP104 per the 28-day period during the 24-week treatment phase, achieved pain freedom at two hours. Initial onset of pain relief began as early as 15 minutes for 16.3% of patients, which continued to improve over time. Additionally, sustained pain freedom was observed in the majority of patients, with 98.4% and 95% of patients reporting no recurrence of their migraine or use of rescue medications during the 24- and 48-hour periods after using INP104 during weeks 21-24. Together, these results suggest that upper nasal delivery may provide an effective, consistent, and well-tolerated alternative to acute oral and injectable treatments for migraine, while potentially providing the reliable efficacy, speed, and potency of the long-established DHE molecule without the need for an injection.

"We believe that these data add to the growing body of clinical evidence supporting the potential of INP104 to be a transformative new therapy for acute migraine. In addition to the STOP 301 study demonstrating INP104's potential to be both safe and well-tolerated when delivered to the upper nasal space, the data showed unsurpassed and sustained patient-reported pain freedom and pain relief rates compared to the best usual care in our exploratory efficacy analyses," said Stephen B. Shrewsbury, M.D., Chief Medical Officer of Impel NeuroPharma. "We believe the low incidence and mild nature of treatment-related adverse events are attributable to INP104's ability to reliably and consistently deliver an optimal low dose of DHE, which may enable patients to benefit from the established efficacy of this trusted molecule, without undesired side effects that may be experienced with higher doses of drug."

Further analysis of STOP 301 data is ongoing and will be submitted for future publication or presentation. Impel NeuroPharma plans to submit a New Drug Application to the FDA in the second half of 2020.

About STOP 301:The Phase 3 STOP 301 study enrolled 360 patients at 36 sites in the United States who had a documented diagnosis of migraine with or without aura, with at least two attacks per month for the previous six months. 354 patients received at least one dose of INP104 and comprised the Full Safety Set. 185 patients who took an average of two or more treatments with INP104 per 28-day period during the 24-week treatment period comprised the Primary Safety Set. Of those enrolled, 74% (n=262) of patients completed the 24-week treatment period. Reasons for treatment discontinuation included withdrawal by subject (n=25 [7.1%]), AEs (n=24 [6.8%]), lack of efficacy (n=21 [5.9%]), lost to follow-up (n=11 [3.1%]), non-compliance/protocol violation (n=5 [1.4%]), and physician's decision (n=1 [0.3%]). A subset of 73 patients continued into a 28-week treatment extension period to 52 weeks total, of which 90% completed.

About INP104:Impel NeuroPharma is currently developing INP104 with the goal to be a transformative new therapy for acute migraine. INP104 aims to optimize dihydroergotamine mesylate (DHE) for fast and lasting whole migraine relief, regardless of when in the migraine attack it is administered, without an injection. Importantly, INP104 is designed to deliver a lower dose of dihydroergotamine mesylate (DHE) compared to FDA-approved and investigational products in development via the nose. This may enable patients to benefit from the established efficacy of DHE, without the undesired side effects that may be experienced with delivery to the lower nasal space.

INP104 utilizes Impel's propellant-enabled POD technology to conveniently and consistently deliver optimal doses of DHE deep into the vascular rich upper nasal space, an ideal target for efficient drug administration, particularly for the majority of patients with migraine who experience nausea and/or vomiting during an attack, which presents limitations for the use of oral therapies, including triptans, CGRP inhibitors and ditans as well as other non-specific acute migraine medications.

About Acute Migraine:Migraine is a common and debilitating neurological disease characterized by recurrent episodes of severe head pain and associated with nausea, vomiting and sensitivity to light and sound.iiMigraine affects approximately 39 million people intheUnited States.iii Of the approximately 19 million diagnosed migraine patients, only four million are on prescription treatment.iv While triptans account for almost 70 percent of migraine therapies, approximately 30 to 40 percent of patients do not respond adequately to triptans and up to 79 percent of the patients who do respond to triptans report being dissatisfied with their current treatment and willing to try a new therapy.v

Further, evidence suggests that gastroparesis, delayed emptying of the stomach, is a prevalent feature in migraine that may delay or reduce the absorption of oral medications, including triptans, gepants and ditans. This means that acute medications can remain in the stomach for hours, delaying symptom relief, leading to loss of confidence (about future administration) and prolonged suffering for the current migraine attack.vi

About Impel NeuroPharma:Impel NeuroPharma, Inc. is a privately held, Seattle-based biopharmaceutical company focused on developing transformative therapies for people living with central nervous system (CNS) disorders with high unmet medical needs.The Company is rapidly advancing a late-stage product pipeline that optimizes the effectiveness of proven treatments for neurological conditions, including INP-104 for acute migraine, INP-107 for OFF episodes in Parkinson's disease, and INP-105 for acute agitation associated with schizophrenia, bipolar I disorder and autism.

IMPEL, POD and the IMPEL Logo are registered trademarks of Impel NeuroPharma, Inc. To learn more about Impel NeuroPharma, please visit our website athttp://impelnp.com.

About Precision Olfactory Delivery or POD TechnologyImpel's proprietary Precision Olfactory Delivery (POD) technology is able to deliver a range of therapeutic molecules and formulations into the vascular rich upper nasal space, believed to be a gateway for unlocking the previously unrealized full potential of these molecules. By delivering predictable doses of drug directly to the upper nasal space, Impel's precision performance technology enables increased and consistent absorption of drug, overriding the high variability associated with other nasal delivery systems.

While an ideal target for drug administration, to date no technology has been able to consistently deliver drugs to the upper nasal space. By utilizing this route of administration, Impel NeuroPharma has been able to demonstrate blood concentration levels for its investigational therapies that are comparable to intramuscular (IM) administration and can even reach intravenous (IV)-like systemic levels quickly, which could transform the treatment landscape for CNS disorders.

Importantly, the POD technology offers propellant-enabled delivery of dry powder and liquid formulations that eliminates the need for coordination of breathing, allowing for self- or caregiver-administration in a manner that may improve patient outcome, comfort, and potentially, compliance.

Migranal is a registered trademark of Bausch Health Companies Inc. or its affiliates.

Contact:Melyssa WeibleElixir Health Public RelationsPhone: (1) 201-723-5805Email: mweible@elixirhealthpr.com

iSilberstein SB. Headache. 2003; 43:144-166; Buzzi MG & Moskowitz MA. Cephalalgia. 1991; 11:165-168; Silberstein SD et al. Headache. 2020; 60:40-57; Migranal Product Information. Available at: https://www.bauschhealth.com/Portals/25/Pdf/PI/Migranal-PI.pdf. Accessed Jan 20, 2020.iiMayo Clinic. Migraine Symptoms & Causes. Last Accessed February 3, 2020.iiiMigraine Research Foundation. Migraine Facts. Last Accessed February 3, 2020.ivData on filevData on fileviAurora S, et al. Cephalalgia. 2013; 33:408-415; Tokola RA et al. Br J Clin Pharmacol. 1984. 18:867-871; Volans GN. Clin Pharmacokinet. 1978 3:313-318

View original content to download multimedia:http://www.prnewswire.com/news-releases/impel-neuropharma-announces-primary-objectives-met-in-pivotal-phase-3-registration-study-of-inp104-for-the-treatment-of-acute-migraine-301073558.html

SOURCE Impel NeuroPharma

Link:
Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine - P&T Community

Does CSF Antibody Testing Confirm Coronavirus in the Brain? – Medscape

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

Testing for antibodies in the cerebrospinal fluid (CSF) may confirm that COVID-19 has invaded the brain.

A case series of three patients attending an inner city US hospital who had severe, laboratory-confirmed COVID-19 and encephalitis shows that while only one had abnormal white blood cells or protein present in CSF, all had evidence of immunoglobulin (IgM) antibodies.

"What was novel about our study was that we were able to show IgM, the acute phase reactant against COVID, in the spinal fluid of these patients, which is a direct indicator they had COVID in their brain," lead author Karima Benameur, MD, a neurologist and associate professor, Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, told Medscape Medical News.

Benameur added that just because CSF testing indicates normal levels of inflammatory proteins, it doesn't mean the virus has not entered the brain and, therefore, to confirm this, she recommends CSF IgM testing, if possible.

The paper was published online June 2 in Emerging Infectious Diseases.

COVID-19 is typically characterized by respiratory illness and viral pneumonia with fever, cough, shortness of breath, and, in severe cases, progression to acute respiratory distress syndrome.

However, there have been few detailed investigations of neurologic complications in COVID-19 infection.

The documented cases include a 31-year-old woman with sickle cell disease who had a recent pulmonary embolus; a 34-year-old man with hypertension and signs of fever, shortness of breath, and cough; and a 64-year-old man also with hypertension and showing typical signs of the virus.

In addition to assessing CSF IgM, researchers analyzed CSF inflammatory proteins and performed molecular testing for SARS-CoV-2 using reverse transcription polymerase chain reaction (PCR).

Two of the patients had normal white blood cell counts and protein levels. "The only reason we could actually diagnose them with COVID encephalitis is because we were able to measure the IgM in their spinal fluid," said Benameur.

Neurologists ordering spinal taps on patients may incorrectly assume there's no brain involvement if the spinal fluid is normal, said Benameur.

Benameur emphasized, "just because the PCR in CSF is negative, this does not mean that the virus has not made it into the brain."

The PCR test is a good test for some viruses, including the herpes virus, but is a poor test for this new coronavirus, she said.

While all three patients had encephalitis, the female patient also developed encephalomyelitis as indicated by inflammation in her brain and spinal cord.

All patients had symptoms affecting cortical and brainstem function at the peak of neurologic illness.

It's not clear how the virus invades the brain, said Benameur. Some speculate it could be through the olfactory nerve, which might explain why some patients lose their sense of taste and/or smell.

Benameur noted that animal research shows that when the virus is injected into nose fibers, it can travel to the brain.

Experts don't know what percentage of COVID patients have the virus in the brain, said Benameur.

In addition, although all of the patients in the current case series were African American, the sample is too small to determine if neurological involvement is more prevalent in this population of COVID patients, said Benameur.

"Overall, having a poor prognosis has been reported to be more frequent in African Americans, but we don't know about neurologic complications. There are not enough subjects for us to be able to do that statistical analysis."

While the three cases were relatively young patients, again, this is not a large enough sample to determine if brain involvement is more likely in younger patients, said Benameur. She noted that she has data from additional patients and there is a wide range of ages.

The two male patients in the current series recovered and were released from hospital. The female patient died.

Her sickle cell disease may have complicated her outcome. Having hypoxia from a condition like pneumonia, in addition to sickle cell disease, may make it more difficult to get oxygen to tissues, said Benameur.

She urged all clinicians seeing COVID patients in clinics, including those without classic symptoms, to "ask them about their cognition."

Commenting for Medscape Medical News, Andrew Wilner, MD, associate professor of neurology, University of Tennessee Health Science Center, Memphis, said reports of neurological complications associated with COVID-19 "continue to multiply" as clinicians gain more experience treating these patients.

"To date, most, if not all, of the neurological complications can be explained by inflammatory changes such as thrombosis or cytokine storm as well as post-infectious causes such as antibody-related Guillain-Barre," said Wilner.

Other complications appear "nonspecific" and "related to acute, severe systemic illness such as hypoxic ischemic encephalopathy due to respiratory failure" as was the case with these three cases, he said.

"Whether unusual symptoms such as loss of olfactory sense are due to direct neuronal injury or inflammation has not been determined."

Wilner noted that although antibodies to the SARS-CoV-2 virus were present in the CSF of the current cases, SARS-CoV-2 RNA was not detected in the CSF.

"As such, this paper is consistent with prior observations that suggest the SARS-CoV-2 virus may cause neurologic injury by secondary mechanisms, but is not specifically neurotropic. Research on this important question is ongoing."

Wilner reports being medical adviser for CVS/Health and receiving royalties from "The Locum Life: A Physician's Guide to Locum Tenens."

Emerg Infect Dis. Published online June 2, 2020. Full text

For more Medscape Neurology news, join us on Facebook and Twitter.

See the original post:
Does CSF Antibody Testing Confirm Coronavirus in the Brain? - Medscape

What you need to know about the COVID-19 pandemic on 13 May – World Economic Forum

A new strain of Coronavirus, COVID 19, is spreading around the world, causing deaths and major disruption to the global economy.

Responding to this crisis requires global cooperation among governments, international organizations and the business community, which is at the centre of the World Economic Forums mission as the International Organization for Public-Private Cooperation.

The Forum has created the COVID Action Platform, a global platform to convene the business community for collective action, protect peoples livelihoods and facilitate business continuity, and mobilize support for the COVID-19 response. The platform is created with the support of the World Health Organization and is open to all businesses and industry groups, as well as other stakeholders, aiming to integrate and inform joint action.

As an organization, the Forum has a track record of supporting efforts to contain epidemics. In 2017, at our Annual Meeting, the Coalition for Epidemic Preparedness Innovations (CEPI) was launched bringing together experts from government, business, health, academia and civil society to accelerate the development of vaccines. CEPI is currently supporting the race to develop a vaccine against this strand of the coronavirus.

1. How COVID-19 is impacting the globe

COVID-19 is a serious disease and causes a wide range of problems from gastrointestinal disease (diarrhoea and nausea) to heart damage and blood clotting disorders. As one virologist pointed out for Agenda this week, it can also cause neurological symptoms in some patients.

Some patients have experienced brain inflammation or even stroke. According to other reports, COVID-19 patients have suffered from GuillainBarr syndrome, a neurological disorder where the immune system mistakenly attacks nerve cells, resulting in muscle weakness and eventual paralysis.

While more research is needed, these symptoms drive home the importance of taking this disease and its long-term effects seriously. Virologist Jeremy Rossman said this information also "highlights the continued importance of preventing viral transmission and identifying those who are, and have been, infected."

Public areas and urban environments could be transformed by coronavirus, according to a Reuters article. Social distancing could create green mazes in public parks while cities could be designed to be more compact to ensure that residents can access goods and services more easily.

"We are in a very experimental stage," said architect Harm Timmermans. "There will be a lot of trial and error, but the notion of the local will definitely be very important."

Parc de la Distance, a new design for a public park by Austrian architecture firm Studio Precht.

Image: Studio Precht, VIA Reuters

Baseball and soccer have returned to South Korea and the measures taken there can provide a glimpse into what might be needed to resume other sports in the months ahead. These might include barely-filled stadiums, crowd noise pumped in through loud speakers, and athletes that trade handshakes for fist bumps.

Truly safe mass events will need something else: a contained virus. South Korea is one of the first countries to contain COVID-19 and other countries will need to follow suit or risk future outbreaks.

Local league baseball has restarted in South Korea, but live audiences arent permitted.

Image: REUTERS/Kim Hong-Ji

Has working from home left you exhausted? You're not alone, explained one expert for the Conversation this week. The self-control needed to manage the demands of working from home can deplete both your mental and physical energies. Finding ways to detach yourself from work can help you you get back on track.

License and Republishing

World Economic Forum articles may be republished in accordance with our Terms of Use.

Written by

Linda Lacina, Digital Editor, World Economic Forum

The views expressed in this article are those of the author alone and not the World Economic Forum.

Follow this link:
What you need to know about the COVID-19 pandemic on 13 May - World Economic Forum

Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of…

Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis

All Patients Demonstrated a Marked and Sustained Reduction in Plasma Arginine

Favorable Safety Profile, Consistent with Previously Reported Results

AUSTIN, Texas, May 26, 2020 (GLOBE NEWSWIRE) -- Aeglea Biotherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced a new 56 week analysis on Arginase 1 Deficiency (ARG1-D) patients who have been treated with pegzilarginase from the Companys completed Phase 1/2 clinical trial and the ongoing Phase 2 open-label extension study. The data were shared yesterday in a virtual, late-breaking oral presentation at the 6th Congress of the European Academy of Neurology.

Arginase 1 Deficiency is a devastating disease that is frequently under diagnosed or misdiagnosed as more common neurological conditions, such as cerebral palsy, due to lack of awareness of this rare condition, said George Diaz, M.D., Ph.D., division chief of medical genetics in theDivision of Medical Genetics and Genomics and Department of Genetics and Genomic Sciences at theIcahn School of MedicineatMount Sinai, New York, NY. Because of the conditions progressive nature, it is essential that patients be diagnosed early, and there is an urgent need for a therapy that addresses the underlying cause of the disease and improves clinical manifestations.

The results of this long-term data demonstrate that treatment with pegzilarginase resulted in a durable clinical response, which is a critical factor in effectively treating a life-long, progressive condition, said Ravi M. Rao, M.B Ch.B PhD, chief medical officer of Aeglea. We are also pleased to see that the lowering of arginine levels observed in the 20 week analysis were maintained through the 56 week analysis. These results align with the primary endpoint of PEACE, our ongoing pivotal Phase 3 clinical trial, and together with the durable clinical response bolsters our belief that pegzilarginase has the potential to be an impactful treatment for people living with Arginase 1 Deficiency.

The presentation, titled 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D), includes data on 13 patients treated with pegzilarginase who completed the 56 week treatment period (8 weeks Part 2 repeat dosing + 48 weeks open-label extension).

Highlights from the 56 week analysis include:

The presentation is available for download on the Presentations & Events section of the Companys website.

About the Phase 1/2 and Open-Label Extension Trial

The Phase 1/2, multicenter, single arm, open-label extension study of pegzilarginase enrolled patients aged 2 years and older with Arginase 1 Deficiency in the United States, Canada, and Europe. The trial investigates single ascending doses (Part 1), repeated weekly dosing for eight weeks (Part 2). The trial enrolled 16 adult and pediatric patients and 14 patients rolled over to the open-label extension. The primary endpoint of the trial is safety and tolerability of intravenous administration of pegzilarginase in patients with Arginase 1 Deficiency. The trial also evaluated the pharmacokinetic and pharmacodynamic effects of repeated doses of pegzilarginase on plasma arginine levels, and evaluation of clinical outcomes using several mobility assessments.

Please visit http://www.clinicaltrials.gov for more information.

About Pegzilarginase in Arginase 1 Deficiency

Pegzilarginase is an enhanced human arginase that enzymatically lowers levels of the amino acid arginine. Aeglea is developing pegzilarginase for the treatment of patients with Arginase 1 Deficiency (ARG1-D), a rare debilitating disease presenting in childhood with persistent hyperargininemia, severe progressive neurological abnormalities and early mortality. Pegzilarginase is intended for use as an enzyme therapy to reduce elevated blood arginine levels in patients with ARG1-D. Aegleas Phase 1/2 and Phase 2 open-label extension data for pegzilarginase in patients with ARG1-D demonstrated clinical improvements and sustained lowering of plasma arginine. The Companys single, global pivotal Phase 3 PEACE trial is designed to assess the effects of treatment with pegzilarginase versus placebo over 24 weeks with a primary endpoint of plasma arginine reduction.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company received approval of its Clinical Trial Application (CTA) for ACN00177 for the treatment of Homocystinuria by the United Kingdoms Medicines and Healthcare Products Regulatory Agency (MHRA). Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit http://aegleabio.com.

Safe Harbor / Forward Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our cash forecasts, the timing and success of our clinical trials and related data, the timing and expectations for regulatory submissions and approvals, timing and results of meetings with regulators, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, the expected impact of the COVID-19 pandemic on our operations and clinical trials, success in our collaborations, the potential addressable markets of the our product candidates and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Media Contact:Kelly Boothe, Ph.D.Director, Corporate CommunicationsAeglea BioTherapeutics512.399.5458media@aegleabio.com

Investor Contact:Joey PerroneSenior Director, Finance & Investor RelationsAeglea BioTherapeuticsinvestors@aegleabio.com

Here is the original post:
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of...

The Effects of Puberty and Menstrual Cycle on Migraine in Girls – Neurology Advisor

Migraine attacks were more frequent in post-pubertal compared to pre-pubertal girls, while the headache characteristics did not differ between the groups, according to study results published in the European Journal of Paediatric Neurology. Findings also suggest that more attacks occur during the follicular vs the luteal phase.

The goal of the current study was to explore the association between migraine attacks and the menstrual cycle in adolescent girls, while taking into account clinical pubertal status and ovulatory cycles. In addition, the study aimed to describe headache characteristics in prepubertal, peri-pubertal and post-pubertal girls with migraine.

The researchers combined 2 different tools to determine the cycle phase and to detect anovulatory cycles: menstrual diary and progesterone saliva measurements.

The prospective study included 47 girls (mean age 12.5 years), including 16 pre-pubertal (mean age 9.8 years), 19 peri-pubertal (mean age 12.6 years) and 12 post-pubertal (mean age 16 years) girls according to Tanner stage and/or menstrual bleeding.

The most important result of the present study is a significant increase in migraine attacks after puberty. Migraine attacks were significantly more common in post-pubertal girls (2820.9 attacks), compared to pre-pubertal (8.89.3 attacks, P =.005) and peri-pubertal (109.8 attacks, P =.012) girls. There were no significant differences between the groups in accompanying symptoms or duration of pain.

Migraine attacks were significantly more common in follicular vs. luteal phase in peri-pubertal and post-pubertal girls (P =.030), but there were no differences in accompanying symptoms, duration of pain and aura between follicular and luteal phase.

There were significant differences in body mass index (BMI) between the groups, as the highest BMI was evident in post-pubertal girls (25.05.5 kg/m2), followed by peri-pubertal (19.52.9 kg/m2) and pre-pubertal (17.12.4 kg/m2) girls. In accordance with previous studies, increased BMI correlated with an increase of migraine attacks.

The study had several limitations, according to the researchers, including the potential limitations of progesterone assays in saliva, inclusion of a well characterized group of girls, and a limited sample size.

Puberty seems to modulate frequency and onset of migraine in girls but not the headache characteristics as a first step towards an adult pattern of migraine, concluded the researchers.

Reference

Bttcher B, Kyprianou A, Lechner C, et al. Manifestation of migraine in adolescents: Does it change in puberty? [published online ahead of print, 2020 Feb 20]. Eur J Paediatr Neurol. 2020;S1090-3798(20)30037-4. doi:10.1016/j.ejpn.2020.02.006

Read more here:
The Effects of Puberty and Menstrual Cycle on Migraine in Girls - Neurology Advisor

Announcing the American Academy of Neurology 2020 Research Program Recipients – Newswise

Newswise MINNEAPOLIS The American Academy of Neurology (AAN), the worlds largest association of neurologists, is pleased to announce the recipients of the 2020 AAN Research Program. This years program has awarded more than $3 million toward neuroscience research and training.

Funding will support the following 2020 AAN Research Program recipients and projects:

Career Development Award Funded by the American Academy of Neurology Oluwole Awosika, MD, Cincinnati, Ohio Hugo Aparicio, MD, Boston, Mass.

Clinical Research Training Scholarship Funded by the American Academy of NeurologyMark Etherton, MD, PhD, Boston, Mass.Carlyn Patterson Gentile, MD, PhD, Philadelphia, Pa. David Lin, MD, Boston, Mass.

Clinical Research Training Scholarship in ALSFunded by The ALS Association and American Brain Foundation, in collaboration with the American Academy of NeurologySarah Berth, MD, PhD, Baltimore, Md.

Clinical Research Training Scholarships in Lewy Body DiseasesFunded by The Mary E. Groff Charitable Trust, the Alzheimers Association, and the American Brain Foundation, in collaboration with the American Academy of NeurologyLenora Higginbotham, MD, Atlanta, Ga.

Clinical Research Training Scholarship in Neuromuscular DiseaseFunded by the Muscle Study Group and the American Brain Foundation, in collaboration with the American Academy of NeurologyPaloma Gonzalez-Perez, MD, PhD, Boston, Mass.

Clinical Research Training Scholarship in Parkinson's DiseaseFunded by the Parkinsons Foundation and American Brain Foundation, in collaboration with the American Academy of NeurologyJames Curtis, MS, CCC-SLP, BCS-S, New York, N.Y.

Clinical Research Training Scholarship in Tourette SyndromeFunded by the Tourette Association of America and American Brain Foundation, in collaboration with the American Academy of NeurologyAlonso Zea Vera, MD, Cincinnati, Ohio

McKnight Clinical Translational Research Scholarship in Cognitive Aging and Age-Related Memory LossFunded by the McKnight Brain Research Foundation through the American Brain Foundation and the American Academy of NeurologyBryan Baxter, PhD, Boston, Mass.Sarah Getz, PhD, Miami, Fla.

Neuroscience Research Training ScholarshipFunded by the American Academy of NeurologyWilliam Zeiger, MD, PhD, Los Angeles, Calif.Richard Krolewski, MD, PhD, Boston, Mass.

Practice Research Training ScholarshipFunded by the American Academy of NeurologyDeanna Saylor, MD, Baltimore, Md.

Richard Olney Clinician Scientist Development Award in ALSFunded by The ALS Association and American Brain Foundation, in collaboration with the American Academy of NeurologyCollin Kreple, MD, PhD, Saint Louis, Mo.

Robert W. Katzman, MD Clinical Research Training Scholarship in Alzheimer's or Related DisordersFunded by the Alzheimers Association and the American Brain Foundation, in collaboration with the American Academy of NeurologyLawren VandeVrede, MD, PhD, San Francisco, Calif.

Susan Spencer, MD Clinical Research Training Scholarship in EpilepsyFunded by the American Epilepsy Society, the Epilepsy Foundation, and American Brain Foundation, in collaboration with the American Academy of NeurologyColin Ellis, MD, Philadelphia, Pa.

Clinician Scientist Development Award in Multiple SclerosisFunded by the National Multiple Sclerosis Society and American Brain FoundationFarinaz Safavi, MD, PhD, Bethesda, Md.

The American Academy of Neurology is the worlds largest association of neurologists and neuroscience professionals, with over 36,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimers disease, stroke, migraine, multiple sclerosis, concussion, Parkinsons disease and epilepsy.

For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

Go here to see the original:
Announcing the American Academy of Neurology 2020 Research Program Recipients - Newswise

The Second Neurologist President of the AHA: His Vision,… : Neurology Today – LWW Journals

By Dawn Fallik May 7, 2020

Mitchell Elkind, MD, MS, FAAN, the president-elect of the American Heart Association (AHA), discusses his career, his vision for AHA, and how COVID-19 will change the field of neurology.

Mitchell Elkind, MD, MS, FAAN, was always fascinated by the mind and brain, and now he's connecting both to matters of the heart. As the president-elect of the American Heart Association (AHA), Dr. Elkind, professor of neurology and epidemiology at Columbia University Vagelos College of Physicians, is the second neurologist to head the organization. The first was former AAN president Ralph L. Sacco, MD, MS, FAHA, FAAN, chairman of neurology at University of Miami Miller School of Medicine

But Dr. Elkind wasn't always focused on biology and physiology. Before going to Harvard Medical School, he earned his undergraduate degree in philosophy at Harvard and his master's degree in the history and philosophy of science at Cambridge University in England. Neurology Today spoke to Dr. Elkind about his plans for the AHA, his thoughts on medical and residency challenges in the time of COVID-19, and why he's grateful for his Peloton bike.

When I was in medical school, I saw the brain as the next frontier of medicine and science, and that's largely been borne out. When I started training, there was maybe one medication for multiple sclerosis; now there are many. I was a resident when IV tPA was approved for stroke and now it's a reality, part of regular treatment for strokes, and that's exciting to see.

I was fortunate to have several great mentors. As a resident, C. Miller Fisher, one of the giants of vascular neurology, was still conducting weekly conferences, and I learned much of the approach to neurological patients, and especially stroke medicine, from him. Other mentors, including Walter Koroshetz, then at Massachusetts General Hospital and J. P. Mohr at Columbia also paved my path. Perhaps the greatest influence on my career, though, has been Dr. Ralph Sacco, now chair at the University of Miami, with whom I continue to collaborate and learn, not just about stroke, but about leadership and commitment. He was also the first neurologist president of the AHA.

In training, during the rotations, you spend a lot of time with patients. They always say you learn neurology stroke by stroke, and it's true. Every patient is different, and neurology is not just about the brain, but the personality and experience of the individual.

You start as a doctor with a lot of intense focus on the patients. But as you choose a specialty and transition from learning to teaching, that shifts, and then you throw research into the mix. So now I'm still seeing patients, but I'm also doing administration, writing grants, teaching...I didn't think about those aspects initially.

I miss some parts of it. Personally, I spend the bulk of my time doing research, so in some ways I'm not primarily a clinician. But if you woke me up in the middle of the night and asked What do you do? I'd say I'm a doctor.' I never wanted to do just one thing, so it's very gratifying to be involved in multiple areas. If I were just seeing patients or I were only in the lab, I think I'd feel like I was missing out. I like to remain open-minded to different experiences - although some people will think that being involved in the American Heart Association is a bit of a left turn for someone in neurology.

I think people don't understand that the AHA is different from the AAN or even the American College of Cardiology. Those are essentially professional organizations, and they are focused on the lives and well-being of those practitioners. The AHA is more of a public health organization focused on prevention and treatment of cardiovascular disease, and that includes strokes. It's got a wide range of activities, and it even began to include brain health a few years ago.

Part of what I hope to do during my tenure is not only to incorporate stroke and other vascular disease of the brain into the message of the AHA, but also brain health and brain science. We just announced our impact goals for 2030, and the mission is to extend the healthy lifespan, free of disability, by two years in the US. There are a lot of neurological diseases that we don't think of as vascular disease, but we have learned that blood vessel disease contributes to dementia and cognitive decline as well. Inflammation of the blood vessels, for example, can lead to blood supply issues to the brain, potentially leading to Alzheimer's and other degenerative diseases.

The AHA has tremendous resources and provides some of the highest levels of grant funding outside of the NIH. I hope members of the neurology community start looking more to AHA for funding.

The treatment of inflammation is an important developing area. It started with cardiology and moved into stroke and it's playing a bigger role in neurology as well. There's a lot of promise there, and we need to continue developing better biomarkers of different diseases as well, both imaging biomarkers and blood biomarkers.

Many have to do with long-term illnesses, like Alzheimer's, where the pathology begins 20 years before people have symptoms. It's hard to know when it's early enough for us to intervene and make a difference. When a disease goes on for so long, when is it right to start treating someone at a young age to prevent something that might happen in old age. We have to think deeply about how we conduct those clinical trials.

Although it's thought of as mainly a respiratory illness, there are implications for cardiology and neurology as well. There is evidence that the virus can enter cells through the ACE2 receptors in heart cells, and these may also be found in neurons. There was some evidence of brain involvement with the original SARS virus, which was also a coronavirus, since it was found in the brainstem in some patients after they died.

People with pre-existing conditions, such as heart disease and stroke, also have a higher mortality from COVID-19.

All of which is to say that we may find there are neurological aspects that people may not be aware of yet. This is a disease that started at the end of December. Now it's March and more than 400 papers have been published about it already. It's amazing how much work has been done.

Trainees are working incredibly hard. It's a challenging situation. They are having to shift from a primarily educational mode to a service mode. We're even bringing people back from retirement. It's an all-hands-on-deck approach. I think resident education might suffer in the short term, and the neurological community will need to consider how best to make up for this. There will be a lot to unpack once we get to the other side. In the meantime, our residents and fellows are doing heroic work, and I am in awe of this generation.

We've been doing telestroke for a long time, and it's filtered out to other areas of medicine. Now our practice has shifted largely to doing outpatient visits by telehealth and we're even doing visits within the hospital that way to minimize contact with COVID-19 patients and preserve personal protective equipment. As a nation, we're fortunate in the sense that telehealth technology started 20 years ago, so it wasn't too hard to fall back on that. We've got to ramp up the internet infrastructure, though, as telehealth may be increasingly used in the future.

I like to cook, and I like to eat. I really like to make pizza, that's my favorite thing. But I'm also trying to stay fit, so I'm glad I recently got the Peloton bike.

Originally posted here:
The Second Neurologist President of the AHA: His Vision,... : Neurology Today - LWW Journals

The History of the World Federation of Neurology – WFN News

The World Federation of Neurology (WFN) was founded in 1957 in Brussels. Although there had been international medical congresses before it, the London Congress of Medicine 1913 was a landmark in the general acceptance of neurology.

The First International Neurological Congress was held in 1931 in Berne. Subsequent meetings took place in London, Copenhagen, Paris and Lisbon. The plurality of several international congresses of neurosciences was one of the reasons the Brussels Congress in 1957 was named The First International Congress of Neurological Sciences.

The movers were two Americans and one European: Houston Merritt, Pearce Bailey Jr. and Ludo van Bogaert, respectively. In 1956, Merritt and Bailey proposed a world neurological federation at a meeting of the AmericanAcademy of Neurology. The National Institute of Neurological Diseases and Blindness (NINDB), National Institutes of Health, U.S., offered an annual grant of $126,190 (U.S.) for five years in order to get the federation started. By the end of 1962, the WFN Secretariat had received more than $500,000 from the original NINDB grant. Thirty-eight national delegates met in Brussels in 1957.

Van Bogaert from Antwerp, Belgium, was a respected neurologist, and the leading neuropathologist of his time. He was elected WFN president, Macdonald Critchley and Auguste Tournay were elected vice presidents and Pearce Bailey was elected secretary-treasurer general.

Van Bogaert established the first Project Commissions (later renamed Research Groups) consisting of international leaders of various sectors of neurology. A series of commissions were established, such as the Research Group on Extrapyramidal Disease organized by Melvin Yahr.

Van Bogaert believed that it was time to create a new and separate organization of the Research Groups. The name of the association would be the World Association of Neurological Commissions (WANC).

There was agreement that Adolphe Franceschetti should become the WANC president and David Klein vice president and secretary-treasurer general. Van Bogaert's successor as president, Macdonald Critchley, thought this was wrong, and that the research arm was essential for WFN in order to survive. Van Bogaert's presidency was successful, but ended in a financial crisis. He had described the three elements of his WFN rescue plan: the increase in annual dues, a decentralization plan and the new organization for the Problem Commissions. The differences of opinion had been dramatic, and John Walton's proposal was to create a new organizational unit of the WFN the Research Committee. The Problem Commissions were renamed Research Groups and organized in the new Research Committee.

Critchley became the next president. During his presidency, WANC became an integral part of the WFN. How could WFN now survive? Critchley was able to see that every cloud had a silver lining. He instilled a feeling of pioneer optimism in the organization. The work of the WFN not only continued, it flourished in spite of a miserable economy. The orientation of the federation remained truly international, harmonious and stimulating.

The reason lay in the vitality of the organization. No new administrative initiatives could be taken, but the activity that had been introduced in the Research Groups was high. How to balance the budget of the WFN?

Were the annual WFN dues too high? Since they had remained unchanged at $2 for 20 years despite inflation, the Finance Committee recommended the dues be raised to $5 on the basis of the WFN's state of bankruptcy. The WFN accountants had to audit all financial statements of the WFN, including those of all Research Groups, and had to urge the national societies that were delinquent in paying their dues.

The Finance Committee also suggested that a Publications Subcommittee of WFN be formed and chaired by Professor Robert Daroff. The subcommittee was charged with development of resources from WFN-sponsored journals, starting with the contracts of the Journal of the Neurological Sciences, Journal of Neuroimmunology, Acta Neuropathologica and the WFN's World Neurology newsletter. It also was decided to have the WFN accountants shift from a cash to an accrual method of accounting commencing Jan. 1, 1987. Any further increase in the number of WFN officers, which would progressively jeopardize WFN's finances, was strongly discouraged.

The WFN Finance Committee recommended that a Fundraising Subcommittee be formed, chaired by Professor Helmut Lechner to investigate. Registration fees, advertisements, exhibit hall rentals and sponsorships were new sources of income.

John Walton took over as the new WFN president in 1998. One of the most central steps of the subsequent WFN re-organization was to establish a corporate status for the association. The impending appointment of officers based in different countries and continents made the creation of a new secretariat pressing. The committee structure had to be reviewed. Financial planning systems, including itemized annual budgets, were introduced and expenditure monitored by the treasurer and reported to the Finance Committee.

It was recommended to separate the offices of secretary-general and treasurer. Following the World Congress in Vancouver, Canada, in 1993, 50 percent of the profits were retained by the host society and 50 percent were transferred to the funds of the WFN, in return for the WFN administrative costs involved in planning the congress and program.

The WFN income increased because of the increase in annual dues and the royalties from its scientific journals. Developments in neurosciences had increased, and effective new drugs were available.

James Toole was the WFN secretary-treasurer general in Richard Masland's administration. They managed to have the new WFN newsletter, World Neurology, survive, and it became an important communication medium for the federation. In 1989, Toole became the editor-in-chief of the Journal of Neurological Sciences.

The U.S. Congress in concert with President George H.W. Bush, declared the 1990s the "Decade of the Brain." In response to a request by the Congress, the Advisory Council of the National Institute of Neurological Disorders and Stroke produced an implementation plan, focusing on 14 major disease categories in which neurological research gives promise of rapid progress for the coming decade. The plan called for increased allocations for basic and clinical neurosciences of $190 million in the first year, rising to $385 million per year in the latter part of the decade.

Jun Kimura was the first vice president in James Toole's administration. He also chaired the Constitution and Bylaws Committee during the critical transition period from the "old" organization to the incorporated WFN. Many of these important projects stemmed from the Strategic Planning Meeting held in St. Albans in 2000, making steady progress in achieving some of the missions agreed upon during those intense discussions.

Johan Aarli had two main initiatives as president of the WFN. He articulated the need to study and develop creative methods to implement improved delivery and increased rural distribution of neurological health, "The Africa Initiative." Second, he was determined to bring into the WFN the 1.2 billion people within The People's Republic of China. This took place at the WFN's Silver Jubilee in 2007.

The Council of Delegates remains the ruling body of the federation. WFN must hold an annual general meeting which all member societies are entitled to attend. It consists of the national delegates of the national neurologic associations. There is a quorum of a meeting of the Council of Delegates if the number of authorized delegates personally present is at least 15.

From 1993, the president, the secretary treasurer general, the first vice president and the chairman of the research committee constituted the WFN Management Committee. Their function was to advise the Council of Delegates and the various committees of the issues of policy and day-to-day management. The WFN Steering Committee was disbanded when the new WFN was organized in 2001.

One major element of the new WFN is the appointment of trustees: the president, the first vice president, the secretary-treasurer general, and three who are elected in accordance with the articles of association, and up to two co-opted individuals. The trustees are charity trustees who have control of the federation and its property and funds.

Two WFN members have contributed to this account of WFN's history: Noshir Wadia: In Service of the WFN, and Jun Kimura: Internal Struggle in Kyoto.

Read original article

Read the original post:
The History of the World Federation of Neurology - WFN News

Cannabidiol Is Safe and Effective for Patients With Lennox Gastaut Syndrome – Neurology Advisor

The following article is part of coverage from the American Academy of Neurologys Annual Meeting (AAN 2020). Due to the global COVID-19 pandemic, the Academy made the necessary decision to cancel the meeting originally scheduled for April 25May 1, 2020, in Toronto. While live events will not proceed as planned, readers can click here catch up on the latest research intended to be presented at the meeting.

Add-on cannabidiol (CBD) was found to be safe and effective for patients with Lennox Gastaut Syndrome (LGS), according to study results intended to be presented at the annual meeting of the American Academy of Neurology (AAN 2020).

Previous studies have suggested that CBD is a safe and effective treatment option for patients with LGS. The goal of the current study was to investigate the long-term profile of add-on CBD in the third analysis of the open label extension (GWPCARE5) of two phase 3, randomized controlled trials (GWPCARE3 and GWPCARE4).

The study cohort included 366 of 368 eligible patients (mean age, 16 years; 54% men; median follow-up, 150 weeks) who completed 1 of the 2 randomized-controlled trials; however, 119 participants withdrew from the study. The participants received plant-derived highly purified CBD (Epidiolex; 100 mg/mL oral solution).

The primary outcome of the study was the safety of CBD treatment; the secondary outcome was the efficacy, based on median percentage change in drop and total seizure frequency.

Treatment with CBD was associated with median percentage reductions in seizure frequency of 48 to 71% for drop seizures and 48 to 68% for total seizures.

During the extended follow-up, adverse events were documented in 96% of the participants, including serious adverse events in 42% of participants and events that led to discontinuation in 12% of participants. The most common adverse events (20%) included diarrhea, convulsion, pyrexia, somnolence, vomiting, upper respiratory tract infection, and decreased appetite.

Although there were 11 deaths during the follow-up period, none were deemed to be treatment-related.

Long-term treatment with add-on CBD in patients with LGS produced sustained seizure reductions, with no new safety concerns, concluded the researchers.

Reference

Patel A, Chin R, Mitchell W, et al. Long-term safety and efficacy of cannabidiol (CBD) treatment in patients with Lennox-Gastaut Syndrome (LGS): 3-year results of an open-label extension (OLE) trial (GWPCARE5). Intended to be presented at the 2020 annual meeting of the American Academy of Neurology. Abstract S25.004.

Here is the original post:
Cannabidiol Is Safe and Effective for Patients With Lennox Gastaut Syndrome - Neurology Advisor

Robots, iPads, and Teamwork – Duke Today

As the COVID-19 epidemic is making neurological emergencies harder to treat--and potentially more dangerous for the patient--neurology providers at Dukes three hospitals are rising to the challenge with robots, iPads, and an unprecedented level of collaboration.

The patient in Durham Regional Hospital was unresponsive to questions. The ambulance had brought him into the emergency room with meningitis, or inflammation around the brain--as well as symptoms that could have been caused by COVID-19.

Now, with the patients condition worsening, neurologist Matthew Ehrlich, MD, MPH, had to weigh the risks and benefits of examining him in person.

Were the benefits of confirming the patients earlier signs of seizure with an EEG worth the risk of possibly exposing an EEG technician (and possibly the rest of the hospital) to infection with the coronavirus? Could Ehrlich assess the patients condition using a virtual consult via an iPad or telestroke robot without exposing himself, or should he enter the room to give an in-person evaluation, opening an avenue for infection for himself, his colleagues, his wife, and family? And were the mans symptoms due to COVID-19, or to any number of unrelated conditions, making all of these concerns irrelevant?

Like he had done many other times in the past few weeks, Ehrlich evaluated his limited information as best he could. An EEG was unlikely to alter the course of treatment for the patient, so that test could be postponed. On the other hand, an in-person neurological assessment would probably help Ehrlich decide on the next steps more effectively than a virtual consult. Ehrlich put on his mask and protective gear, and entered the room to see the patient.

Matt Ehrlich, MD, MHS

Neurological emergencies were dangerous before the COVID-19 pandemic. Stroke, traumatic brain injury, severe seizures, and other conditions require a rapid, coordinated response by a team of experts. Emergency medical technicians, neurologists, advanced practice providers, emergency medicine doctors, imaging technicians, physical and speech therapists, and others all play a role in transporting patients, deciding on the proper form of treatment, and in beginning the long rehabilitation process.

The constant potential for COVID-19 transmission has disrupted the way hospitals respond to these emergencies. It may also be making these conditions more dangerous. Now, providers like Ehrlich have to decide how to provide treatment while also keeping our providers (and the hospital system) safe from infection. Theyre making these decisions in close quarters, with limited supplies, without established procedures or guidebooks, and with our intensive care units more crowded than ever.

(Note: Do not hesitate to call 911 if you or someone you know is experiencing a heart attack or stroke. These emergencies require prompt medical care, and our hospitals are taking steps to make sure all of our providers and patients are safe. Delaying treatment increases the likelihood of early death or a permanent disability.)

Teams at Dukes three hospitals have turned to a combination of technology and an unprecedented level of teamwork to rise to this challenge. Technology in the form of iPads and robots originally designed for telestroke visits, allow providers to interact with patients without ever having to come in close physical contact. And teamwork and communication, both within and across the hospital systems, allow the hospital neurology teams to share information and coordinate strategies in a situation that is evolving and changing on a daily basis.

The robot sitting in a corner

Over the past two months, office workers across the country have come to rely on teleconferences to connect with their colleagues. DukeHealth and other health systems have also accelerated their ability to provide virtual clinic visits. Hospital providers, however, cant just Zoom in to a meeting with their patients.

To start, there arent enough desktop or laptop computers to go around. And in order to function and be safe, any teleconferencing device would have to be easily transportable, user friendly, and capable of being sterilized between users.

As it turns out, Duke Raleigh and Duke Regional Hospitals had been using equipment that fit all of those requirements for years. Both hospitals were already equipped with telestroke robots, or remote-controlled machines with two-way cameras. During night hours when a neurologist is not present, these machines allowed off-site neurologists to evaluate and treat patients who are having strokes.

Now, nurse practitioner Stacey Bennett, MSN, can give lessons about risk reduction, and answer questions about life after stroke without having to enter the same room as a potential COVID-19 patient. We had previously only used the robots during off hours. During the day it just sat there in a corner. We took the initiative to use it to start talking to people.

Stacey Bennett, MSN

Other providers such as neurologists like Ehrlich, advanced practice providers, or speech or physical therapists, also use the robot interact with patients without potentially exposing themselves, their colleagues, or other patients to infection (a nurse or other caregiver who is already in the same room as the patient can help guide the robot and facilitate any provider-patient interactions).

The robots were especially useful during the earliest days of the pandemic, when masks and other protective equipment were in short supply, but they continue to be in use in both Duke Regional and Duke Raleigh Hospitals.

These machines have made things safer for everyone while still allowing patients to get the care they need, said Bennett. We all feel really fortunate that we have it. The Neurology team at Duke Regional has since supplemented their telestroke robot with eight modified iPads that allow provider-patient interaction via Facetime.

One of Duke Regional Hospital's eight modified iPads, nicknamed "Dr. K. Rona," allows patients and providers to interact without increasing the risk of spreading the coronavirus.

Working together, within and across Duke hospitals

More important than any technological advance, however, is the teamwork and communication that have allowed Dukes providers to work in teams within and across hospitals to respond to this crisis.

Within Duke Regional, teamwork across service lines enabled the telestroke robots success. At first, every surface of the robot had to be thoroughly scrubbed and disinfected every time it went in and out of a room. This laborious process took nearly 10 minutes and potentially exposed a health-care worker to infection with every scrubbing.

Using draping equipment borrowed from Regionals Surgery Department and under guidelines from their Infectious Disease colleagues, Bennetts team were able to obtain sheeting that covered the robots and could be quickly replaced between uses.

The COVID-19 pandemic has also accelerated group trainings, communication, and shared standards of care for neurology care in Duke University Hospital, Duke Regional Hospital, and Duke Raleigh Hospital. This January, providers from all three hospitals held a hospital neurology summit to work together to identify problems, build on strengths, and find ways to help patients. This group was made of an inclusive group of providers, with advanced practice providers, stroke managers, and other experts as well as neurologists all taking part in the discussion.

The summit really allowed us to put a face to a name and identify as one team of neurohospitalists. We made a pledge to have each other's back and choose to work on things together. said Bennett. The goal became helping each other actually improve patient care instead of trying to get each other to be the same.

Members of this summit from all three hospitals have stayed in touch throughout the COVID-19 pandemic, discussing how to protect themselves, how to deliver care at a distance, and ways that COVID-19 might influence what happens during a stroke or other neurological emergency. Theyve also undergone group trainings so that providers at one Duke hospital can cover colleagues at another if needed.

We try new things together. We keep one another in the loop and let each other know how things are going. We are encouraging to each other. We respect our team members opinions and ideas. I have never felt more supported by my community as a healthcare worker, Bennett said.

Ehrlichs patient eventually tested negative for COVID-19. The patient did, however, have bacterial meningitis, an acute medical emergency, as well as a related infection in his bloodstream. Thanks to his prompt treatment, the patient was able to recover and has since returned home.

The steps Ehrlich takes to return home every day have evolved into a routine. He enters his house through the garage to prevent his dog or two-year-old daughter from jumping on him before he can strip, bag his work clothes and shoes, scrub his phone, keys, and wallet with Lysol, and hop straight into the shower. It takes a while before I can go back to feeling like a human being again, Ehrlich said.

Still, Ehrlich remains confident about his and his colleagues ability to provide care throughout the rest of the pandemic.

"The coronavirus pandemic has really shone a spotlight on the innovative, collegial, and collaborative nature of our stroke and neurohospitalist teams. Though we've sailed into largely uncharted waters over the past couple months, the incredible response from our Duke teams shows we can weather the storm, and continue to provide top-notch care to our patients during these difficult times," Ehrlich said.

Go here to read the rest:
Robots, iPads, and Teamwork - Duke Today

COVID-19 on the brain: BBC News at the National Hospital for Neurology and Neurosurgery – University College London Hospitals

BBC medical correspondent Fergus Walsh met with NHNN patient Paul Mylrea, 64, who is making a remarkable recovery after suffering two major strokes triggered by COVID-19 infection.

Im very lucky in physical terms but it has been tough, said Paul who had previously been very healthy and active and had a passion for diving.

After my second stroke, my wife and daughters thought that was it, they would never see me again. The doctors told them there was not much they could do except wait. Then I somehow survived.

Pauls first stroke was caused by a blood clot in his brain and happened while he was recovering from COVID-19 at University College Hospital. The clinical team also found blood clots in his lungs and legs so prescribed powerful blood-thinning drugs.

A couple of days later, however, he suffered a second, even bigger stroke and was transferred to the NHNN for specialist care.

Pauls consultant neurologist, Dr Arvind Chandratheva, said: I immediately assumed the blood-thinning drugs had caused a bleed in the brain but what we discovered was unlike anything we have seen before.

Despite the blood-thinning treatment, Pauls second stroke had been caused by another clot in his brain and blood tests showed that he had extraordinarily high levels of a clotting marker called D-dimer. Normally these levels are less than 300 and can rise to 1,000 in stroke patients but in Pauls case they were 80,000.

"I've never seen that level of clotting before something about his body's response to the COVID-19 infection had caused his blood to become incredibly sticky," said Dr Chandratheva.

It puzzled us why a fit and healthy man had experienced so many blood clots in rapid succession, despite blood-thinning treatment. But in just two weeks in April 2020, our team saw six people with COVID-19 who had similar strokes caused by a blocked, large artery in the brain.

We were witnessing the unfolding of a distinctive pattern of stroke associated with the pandemic.

Specialists at the NHNN have also seen an increase in COVID-19 patients with extensive inflammation in the brain. They do not think this is caused by COVID-19 itself but by the bodys immune system overreacting to the disease.

Consultant neurologist Dr Michael Zandi said: We are starting to see a number of effects of COVID-19 on the brain which are very concerning. For some people it could be devastating and life-altering.

We need to be prepared for decades of impact on peoples brains and mental health. The closest comparison we have is the 1918 flu pandemic when a lot of brain disease and problems emerged over the following 10 to 20 years."

Paul, who is a leading communications professional and speaks six languages, spent five weeks in hospital but is now recovering extremely well at home.

In the BBC report, we see Paul having online neurorehabilitation with clinical psychologist Dr Catherine Doogan and occupational therapist Kate Kelly as part of the N-ROL programme. The programme is led by Professor Nick Ward and supported by fundraising efforts by the charity SameYou to allow people to continue with their rehabilitation at home during the pandemic.

Paul said: I have been getting progressively stronger thanks to the ongoing care of the NHNN.

Here is the full news report, online articleand podcast(at 22m 20s).

For further information also see an article featuring Dr Chandratheva in The Conversation.

Continued here:
COVID-19 on the brain: BBC News at the National Hospital for Neurology and Neurosurgery - University College London Hospitals

How a Rural Hospital Developed and Launched its Telehealth Platform – mHealthIntelligence.com

August 11, 2020 -Small hospitals across the country are turning to telehealth to expand their treatment options and give patients access to specialists they might otherwise have to travel long distances to see. These services not only improve care for patients, but help the hospital to keep that care in the community.

Such is the case with the Beauregard Health System, an acute care hospital in rural DeRidder, LA. This past June, the 49-bed not-for-profit hospital launched a platform, through a partnership with SOC Telemed, to provide critical care, psychiatry, in-patient and emergency neurology and cardiology services via telemedicine.

The need for cardiology services was especially important. The hospitals only full-time cardiologist had left the previous April, and the hospital was transferring, on average, 30 patients each month to other hospitals.

Our community was vulnerable without a full-time local cardiologist, Traci Thibodeaux, MHA, CMPE, Beauregards chief operating officer, said in a press release. We wanted to partner with a cardiology group in Lake Charles, but knew they couldnt meet our needs for an onsite full-time physician.

In a recent Q&A with mHealthIntelligence, Thibodeaux explains how Beauregard planned out and launched its connected health strategy.

READ MORE: Telehealth Is The Best Tool in the Healthcare Toolbox for FQHCs

Q. What was the thinking behind deciding to partner with a telehealth company to offer these services on a telemedicine platform?

A. Beauregard Health System decided to partner with a telehealth provider because we needed to evolve from our grass roots approach and expand to include additional specialists - on one platform, using one process and the same equipment - to make it as seamless as possible for patients, nursing, and physicians.Since we are small rural acute care hospital, there are some specialties that we know well never offer locally.

Q. How were these 5 specialties psychiatry, critical care, inpatient neurology, emergency neurology and cardiology chosen? Were there specific arguments that these particular specialties need to be included in a telehealth strategy?

A. The specialties are critical for various reasons.

With psychiatry, our Emergency Department can get overwhelmed with trying to care for the sensitivities and complexities that this patient population presents.We have to consider patient safety, staff safety, and the safety of other patients and families, which includes children.We want all of our patients and families to feel safe and well cared for in our facility.

READ MORE: Telecritical Care Expands Telehealth From the ICU to Where Its Needed

Tele-psych consultation allows us to expeditiously determine the best and safest course and place of treatment, which often requires a transfer to a more appropriate care setting.

Cardiology and Neurology are important because, without these consultations, patients were automatically transferred to other facilities for a higher level of care, whether or not they truly needed it, since we werent able to offer on-site cardiology and neurology evaluations.

Telemedicine creates an opportunity to keep patients local when it is safe to do so.Our team on the ground, in consultation with a specialist who has assessed the patient, effectively care for many patients using this approach.This prevents unnecessary disruption for patients and families (and) prevents adding unnecessary direct and indirect cost of care for families, which includes transportation, travel, lodging, insurance, child care and missed work.

When we launched Tele-Critical Care in December of 2019, we had no way of knowing what a profound impact this would have on our patients, nurses, physicians and community.We were perfectly positioned to effectively care for every wave of COVID 19 that we first started seeing in March of this year at our hospital and through our current peak.This has allowed us to provide excellent care and weve undoubtedly gained a tremendous amount of community trust and support.

Q. What are the biggest challenges in launching a telehealth platform to address these services?

READ MORE: Senators Propose $50M Program to Fund RPM Pilots in Rural Areas

A. The biggest challenges were uncertainty of utilization and success.We questioned whether we would have a return on our investment with insurance plans reimbursing the service.We hoped that nursing would support the technology and see it as value-add for patient care.We prayed that the patient and family would have a great experience.We worried that we would have the WiFi and audio/video quality to support the interaction without interruption. We questioned whether the patient and family would have a good experience without the face to face interaction.

Q. How were clinicians and other staff brought on board? Was there any pushback or concerns about moving to telehealth?

A. The medical staff and board members were supportive of the project, but I might generalize that they were all cautiously optimistic going into this. Before COVID 19, the support of specialists were nice to have, but not essential, as we would transfer higher risk patients out for higher level of care.

Mid-pandemic, the medical staff and board have been so supportive that the telemedicine project has evolved and expanded into an organizational strategy.Tenured physicians who have practiced traditional medicine and bedside care are extremely supportive and accept that telemedicine is here to stay.

Ive (also) gotten additional feedback from nurses in the units who have learned from the online physician, as theyve had to be the hands of these virtual physicians.Nursing has to be on point in communicating vitals, assisting with the evaluation and assessment as directed by the on-screen physician and reporting pertinent details and changes in status.As one of our seasoned ICU nurses stated, I have to be prepared and on my game.Its made me a better nurse.

Q. Had you looked at other health systems/hospitals to see how they adopted telehealth? If so, what lessons were learned in how they did this?

A. At the time we were gearing up to launch telemedicine, our organization was also shopping for a new electronic health record. While we were checking references and networking with users of the various systems, we would ask about telemedicine and virtual visit capabilities.Most facilities had Tele-Stroke programs (as did we) but were not yet offering robust inpatient telemedicine services.

We had a need to stop unnecessary transfers; we realized that telemedicine was more of a sure thing than our ability to successfully recruit for the needed specialties. We decided to forge ahead with telemedicine and were determined to make the technical and logistics side work.At that point, the biggest wild card was whether the patient and family would have a positive experience and the service would add-value to our hospitalists and community physicians.

Q. What advice would you give a similar-sized hospital about launching a telehealth strategy?

A. Design your implementation strategy with a multi-disciplinary team. While medical staff and board support are certainly foundational to the strategic plan and investment, youve got to have champions -namely, physician (such as hospitalist leader or CMO), executive sponsor, IT, nurse leader, nurse educator, clinical workflow and documentation, heath information, contracting and revenue cycle.This team will have to collaborate on workflow, logistics and the what-ifs.

It is best to have folks involved on the front-end so that they buy in, remain engaged and have enough knowledge and familiarity to help trouble-shoot the workflow at go-live. If you have the right folks, a sense of pride and ownership develops, and failure is not an option.

Q. How will you measure success for these services? What benchmarks are being used to note whether a particular program is improving care or reducing workload stress?

A. We expect to see the number of patients we are transferring out by service line decrease, as compared to the baseline data prior to our telemedicine launch.We expect to find our case mix index trend up a little, as we are caring for slightly more complex patients relative to neurologic, cardiovascular and critical care. We expect a corresponding uptick in revenue relative to the level of care provided.

We expect to see physician satisfaction improve, since they will be better supported by specialists that we didnt previously have access to. We expect our patient experience to be impacted since the engagement between the patient and family and on-screen physician has been remarkable from a patient experience perspective.

For example, over the weekend we were able to keep and care for two neurology patients who we might have otherwise transferred out prior to telemedicine.Weve effectively cared for critically ill patients.Weve also been able to survive the challenges of the COVID 19 pandemic, while so many other hospitals have had to lay off staff or close their doors.In addition, weve provided our medical staff with access to specialists that we would not have otherwise had.

The most surprising aspect of our telemedicine program is how the nursing staff appreciates being able to provide more comprehensive care for their patients, how the nursing staff is able to learn from the on-screen physician, and how well-received the service has been with our patients who had mostly only been exposed to face-to-face care.

Q. How will you scale up or expand your telehealth strategy in the future?

A. We look forward to launching virtual visits in conjunction with our patient portal and the new EHR, which goes live January 1, 2021. We are exploring other specialties and virtual services (and) are open to any virtual opportunity that is affordable, sustainable, and adds value to our patients and medical staff.

Q. What can or could state and federal officials do to help hospitals like yours use more telehealth?

A. The loosening of some regulations related to telemedicine has been a great start, but it is in response to COVID 19, and were not certain what the new regulatory normal looks like.Especially burdensome for providers is the ongoing battle with insurance plans to figure out which hoops they require to approve services and then, even more challenging, is how to get reimbursement.There are very few standard rules of engagement. Every plan has its own requirements and nuances, which is frustrating, discouraging, labor intensive and costly.

Especially for rural communities, we need more planning and investment in infrastructure to support access to care, such as fiber networks, affordable internet and device availability for home monitoring systems for elderly and other at risk populations.Additionally, shifting focus to programs that support more population health initiatives and comprehensive and sustainable programs to close the gap on disparities in health care is crucial.

Continue reading here:
How a Rural Hospital Developed and Launched its Telehealth Platform - mHealthIntelligence.com

Could the keto diet’s benefits be linked to changes in the gut microbiota? – Gut Microbiota for Health

Although the ketogenic (or keto) diet was initially used for treating childhood refractory epilepsy in the 1920s, fasting has been used to treat epilepsy since 500 BC. Later on, variations of the ketogenic diet (such as the Atkins diet) have appeared and its use has extended into adults for purposes other than reducing seizure frequency. They include treating weight loss, metabolic syndrome, certain cancers and psychiatric disorders such as Alzheimers disease.

This high-fat diet resembles the physiological effects of fasting by restricting carbohydrate intake to between 20g and 50g non-fiber carbohydrate per day (an average person in an industrialized country consumes 200g carbohydrate per day). This means replacing grains, fruit, starchy vegetables, legumes and sweets with carb-free or very low-carb foods such as non-starchy vegetables, cheese, avocados, nuts and seeds, eggs, meat, seafood and olive or coconut oil for cooking and dressing. That fat is then turned into ketone bodies in the liver, which can be taken up and used to fuel the bodys cells.

While scientists still struggle with figuring out which mechanisms underlie the keto diets therapeutic benefits, the gut microbiota, epigenetic changes and metabolic reprogramming appear to be involved in the response to diet.

Elaine Hsiao and her colleagues found that the microbiome is required for the anti-seizure effects of the keto diet. When germ-free mice received stool from mice on a keto diet, seizures were reduced, with Akkermansia muciniphila and Parabacteroides being involved in reducing electrical activity in the brain.

This has led scientists to explore whether the keto diet might be worth considering in gastrointestinal disease.

A new study in mice and humans, led by Peter J. Turnbaugh from UC San Francisco, breaks down the effects of the keto diet on the gut microbiome involving a reduction in bifidobacteria levels and pro-inflammatory Th17 immune cells.

First, Ang and colleagues assigned 17 men who were overweight or obese (but non-diabetic) to a control diet for 4 weeks, followed by the keto diet for 4 weeks. Metagenomic sequencing revealed bifidobacteria speciesin particular Bifidobacterium adolescentisdecreased the most on the keto diet.

The authors were also interested in exploring whether these changes were specific to the keto diet or were also observed in the high-fat and high-carbohydrate diet that is known to promote metabolic disease in mice by inducing shifts in the gut microbiome. To this end, Ang and colleagues fed groups of mice with high-fat diets formulated with graded levels of carbohydrates. It turned out that Bifidobacterium levels decreased with increasing carbohydrate restriction, thus highlighting that carbohydrate restriction, rather than high-fat intake, is the main contributor to the keto diets impact on the gut microbiome.

The mucus layer was maintained in the absence of dietary carbohydrates and bile acid metabolism was not affected. This led the authors to test whether ketone bodies themselves could be directly responsible for the progressive decreasing of Bifidobacterium as carbohydrates decreased.

Feeding mice with the high-fat diet and high-carbohydrate diet or the keto diet supplemented with a synthetic ketone esterdeveloped for mimicking ketosis without modifying dietled to increased levels of beta-hydroxybutyrate ketone bodies in the intestinal lumen and less adiposity. That can be explained by the fact that, beyond the liver, intestinal epithelial cells are also a source of ketone bodies.

Interestingly, in vitro experiments in human stool samples and work in rodents showed that ketone bodies selectively inhibited bifidobacterial growth in a dose- and pH-dependent mechanism. While other members of the gut microbiota were also affected to a lesser extent, the selective inhibitory effects of ketone bodies on Bifidobacterium may involve changes at the gut ecosystems ecological level and warrants further research.

Finally, both mono-colonization of germ-free mice with B. adolescentisthe most abundant species in the baseline diet that experienced the most marked decrease after going on the keto diet and human microbiome transplantations into germ-free mice showed that the keto diet mediates the lack of intestinal pro-inflammatory Th17 induction by reducing colonization levels of B. adolescentis. The observed differences in the gut were also detected on Th17 cells in the visceral adipose tissue.

To sum up, this study shows that the keto diet induces changes in the gut microbiome characterized by marked suppression of bifidobacteria coupled with a decrease in intestinal Th17. Said reduction would be worth considering in the context of improving obesity and immune-related diseases with increased Th17 activation.

The results reported here regarding changes in beneficial bifidobacteria, together with gut-related side effects and the nutritional safety of the keto diet due to the exclusion of major food groups, warrants caution on the use of this diet for managing gut symptoms or gastrointestinal disease progression.

References:

Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the international ketogenic diet study group. Epilepsia Open. 2018; 3(2):175-92. doi: 10.1002/epi4.12225.

Wheless JW. History of the ketogenic diet. Epilepsia. 2008; 49(Suppl. 8):3-5. doi: 10.1111/j.1528-1167.2008.01821.x.

Tuck CJ, Staudacher HM. The keto diet and the gut: cause for concern? Lancet Gastroenterol Hepatol. 2019; 4(12):908-9. doi: 10.1016/S2468-1253(19)30353-X.

Cabrera-Mulero A, Tinahones A, Bandera B, et al. Keto microbiota: a powerful contributor to host disease recovery. Rev Endocr Metab Disord. 2019; 20(4):415-25. doi: 10.1007/s11154-019-09518-8.

Olson CA, Vuong HE, Yano JM, et al. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell. 2018; 173(7):1728-41. doi: 10.1016/j.cell.2018.04.027.

Ang QY, Alexander M, Newman JC, et al. Ketogenic diets alter the gut microbiome resulting in decreased intestinal Th17 cells. Cell. 2020. doi: 10.1016/j.cell.2020.04.027.

Turnbaugh PJ, Backhed F, Fulton L, et al. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008; 3:213-23. doi: 10.1016/j.chom.2008.02.015.

Newport MT, Vanltallie TB, Kashiwaya Y, et al. A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimers disease. Alzheimers Dement. 2015; 11(1):99-103. doi: 10.1016/j.jalz.2014.01.006.

Reddel S, Putignani L, Del Chierico F. The impact of low-FODMAPs, gluten-free, and ketogenic diets on gut microbiota modulation in pathological conditions. Nutrients. 2019; 11(2):373. doi: 10.3390/nu11020373.

Read the original:
Could the keto diet's benefits be linked to changes in the gut microbiota? - Gut Microbiota for Health

Association between the high risk for obstructive sleep apnea and intracranial carotid artery calcification in patients with acute ischemic stroke. -…

Obstructive sleep apnea (OSA) is an independent risk factor for stroke. Furthermore, intracranial carotid artery calcification (ICAC) is a marker for subclinical atherosclerosis and future cardiovascular events. We investigated the association between the high risk for OSA and ICAC in patients with acute ischemic stroke.We retrospectively investigated 73 patients who were admitted to the hospital with acute ischemic stroke in the internal carotid artery (ICA) territory due to large-artery atherosclerosis. The risk for OSA was assessed using the Berlin Questionnaire, and patients were classified into low-risk (LR-OSA) and high-risk groups (HR-OSA). We compared the burden of ICAC between the two groups. Univariable and multivariable analyses were conducted to investigate the association of high risk for OSA with the presence of calcium in intracranial ICA.The HR-OSA group of 35 patients (48%) was significantly older and had a higher rate of hypertension and diabetes mellitus than the LR-OSA group. The HR-OSA group had more frequent ICAC (92% vs. 63%, p<0.001), higher Agatston score (162.0 vs. 8.5, p<0.001), and greater total volume of ICAC (261.2 mm vs. 20.1 mm, p<0.001) in the intracranial ICA. Presence of calcium in symptomatic intracranial ICA was positively correlated with age (odds ratio, OR, 1.432; 95% confidence interval, CI, 1.098-1.868) and HR-OSA (OR, 18.272; 95% CI, 0.500-668.401) in multivariable logistic regression analysis.This study showed that the presence of calcium in symptomatic intracranial ICA was related to high risk for OSA in patients with acute ischemic stroke.

PubMed

See more here:
Association between the high risk for obstructive sleep apnea and intracranial carotid artery calcification in patients with acute ischemic stroke. -...